anonymous
Guest
anonymous
Guest
Hot takes:
1. Entire board should be replaced for not going after an acquisition even though Michel and team made a very strong case. Now there's not as much $$ out there to find a deal that would transform the company.
2. Why was this guy picked again?
3. Entire leadership needs to be swept out. Morale couldn't be lower.
4. Find the person's that signed off on selling hemophilia, Ocrvus and biosimilars and get rid of them too.
5. All Biogen had the last 3 years is bad news.
6. I think Michel is partially a scapegoat here. Some of this falls on the board.
7. Legal team needs to be fired before they waste more resources suing to overturn the coverage decision. They never win anyways!
1. Entire board should be replaced for not going after an acquisition even though Michel and team made a very strong case. Now there's not as much $$ out there to find a deal that would transform the company.
2. Why was this guy picked again?
3. Entire leadership needs to be swept out. Morale couldn't be lower.
4. Find the person's that signed off on selling hemophilia, Ocrvus and biosimilars and get rid of them too.
5. All Biogen had the last 3 years is bad news.
6. I think Michel is partially a scapegoat here. Some of this falls on the board.
7. Legal team needs to be fired before they waste more resources suing to overturn the coverage decision. They never win anyways!